Am Fam Physician. 2002 Jun 1;65(11):2212-2214.
to the editor: I read with interest your article, “Treatment of Hypothyroidism.”1 I found the article informative, but I do have one disagreement. Dr. Hueston’s discussion of “subclinical hypothyroidism” suggests that patients with thyroid-stimulating hormone (TSH) levels between 6 and 10 may not progress to overt hypothyroidism and do not necessarily need to be treated. The author recommends an “individualized” approach and gives several parameters to aid in decision-making. One important factor is missing from this discussion: the lipid panel. Patients with “mild thyroid failure” (the new term for subclinical hypothyroidism, since many of these patients have a real clinical problem) usually have dyslipidemia, which may be improved with thyroid hormone replacement. Indeed, mild hypothyroidism is a risk factor for atherosclerosis.
I had the benefit of serving on two expert panels on this illness (funded by the makers of Synthroid). However, lead investigators have convinced me that all patients with an elevated TSH level should be treated unless a contraindication is present. Improvement in several health parameters are often observed in patients who receive treatment, including improved well-being (patients who did not realize they were tired until they felt better), improved lipid panel, and modest weight loss. These patients are often overweight and lose weight much easier when their TSH is normal.
In summary, I consider patients with an elevated TSH level as having hypothyroidism, and patients with normal free thyroxine (T4) level as having mild thyroid failure, which is a real condition. Why should physicians wait to treat these patients until they, if ever, progress to worse disease? Early treatment is beneficial, especially considering the lipid profile that results from an elevated TSH level.
1. Hueston WJ. Treatment of hypothyroidism. Am Fam Physician. 2001;64:1717–24.
Letters to the Editor
in reply: I appreciate Dr. Scherger’s comments regarding my article1 on hypothyroidism in AFP. The issue of small elevations of thyroid-stimulating hormone (TSH) with normal thyroxine (T4) levels is still controversial. While it is recognized that hypothyroidism is clearly associated with elevations in cholesterol (and hypercholesterolemia),2 there are no population-based data showing that persons with subclinical hypothyroidism are more likely to have higher cholesterol levels. Treatment studies of thyroid in this population have had only a small number of participants,3–5 included patients with elevated TSH levels after thyroid ablation therapy,4 and have not compared the effects of thyroid replacement therapy with other treatment modalities for hyperlipidemia, such as statins. So, I do not believe it is clear that the best course of treatment for these patients is thyroid replacement.
However, given these limitations, a patient at high risk for cardiac disease (e.g., a woman who has had a previous cardiovascular event, has diabetes, is a smoker, or has a strong family history of atherosclerosis) treatment for subclinical hypothyroidism with low doses of thyroxine probably carries more benefits than risks. For elderly, white women (which is the typical demographics of this population) with low risk of cardiac disease, the risk of osteopenia from excessive thyroid use may outweigh any benefits of thyroid replacement. Therefore, I think we must individualize care for our patients with this condition rather than advocating blanket therapy with thyroxine.
REFERENCESshow all references
1. Hueston WJ. Treatment of hypothyroidism. Am Fam Physician. 2001;64:1717–24....
2. Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Study. Atherosclerosis. 2001;155:195–200.
3. Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg PA, Lindstedt G. A double-blind crossover 12-month study of L-thyroxine treatment of women with ‘subclinical’ hypothyroidism. Clin Endocrinol (Oxf). 1988;29:63–75.
4. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo-controlled trial. Ann Intern Med. 1984:101:18–24.
5. Jaeschke R, Guyatt G, Gerstein H, Patterson C, Molloyt W, Cook D, et al. Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism?. J Gen Intern Med. 1996;11:744–9.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2002 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions